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Drug Reaction with Eosinophilia and Systemic Symptoms
(DRESS) / Drug-Induced Hypersensitivity Syndrome (DIHS): 
a review of current concepts*
Reação a drogas com eosinofilia e sintomas sistêmicos (DRESS) / Síndrome da
hipersensibilidade induzida por droga (DIHS): revisão dos conceitos atuais
Paulo Ricardo Criado1 Roberta Fachini Jardim Criado2
João de Magalhães Avancini3 Claudia Giuli Santi1
Abstract: The Drug Reaction with Eosinophilia and Systemic Symptoms syndrome, also known as Drug Induced
Hypersensitivity Syndrome presents clinically as an extensive mucocutaneous rash, accompanied by fever, lymp-
hadenopathy, hepatitis, hematologic abnormalities with eosinophilia and atypical lymphocytes, and may involve
other organs with eosinophilic infiltration, causing damage to several systems, especially to the kidneys, heart,
lungs, and pancreas. Recognition of this syndrome is of paramount importance, since the mortality rate is about
10% to 20%, and a specific therapy may be necessary. The pathogenesis is related to specific drugs, especially the
aromatic anticonvulsants, altered immune response, sequential reactivation of herpes virus and association with
HLA alleles. Early recognition of the syndrome and withdrawal of the offending drug are the most important and
essential steps in the treatment of affected patients. Corticosteroids are the basis of the treatment of the syndro-
me, which may be associated with intravenous immunoglobulin and, in selected cases, Ganciclovir. The article
reviews the current concepts involving this important manifestation of adverse drug reaction.
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Resumo: A síndrome Reação a Drogas com Eosinofilia e Sintomas Sistêmicos, também conhecida como
Síndrome da Hipersensibilidade Induzida por Droga apresenta-se clinicamente como uma erupção cutâneo-
mucosa extensa tipo exantemática, associada a febre, linfadenopatia, hepatite, anormalidades hematológicas com
eosinofilia e linfócitos atípicos, e pode envolver outros órgãos, produzindo insuficiência renal, infiltrado eosino-
fílico cardíaco e pulmonar, além de pancreatite. O reconhecimento desta síndrome é de suma importância, uma
vez que, a taxa de mortalidade é de cerca de 10% a 20% e uma terapia específica pode ser necessária. Sua etio-
patogenia está relacionada a drogas específicas, principalmente os anticonvulsivantes aromáticos, alterações imu-
nes, reativação sequencial de herpesvirus e associação com alelos do HLA. O pronto reconhecimento da síndro-
me e a retirada da droga desencadeante são os passos mais importantes e essenciais no tratamento dos doentes
acometidos. Os corticosteróides são as medicações de escolha para o tratamento da síndrome, podendo ser asso-
ciados imunoglobulina intravenosa e em, alguns casos selecionados, Ganciclovir. O artigo traz uma revisão dos
conceitos atuais que envolvem essa importante manifestação de reação adversa a drogas. 
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Drugs involved and metabolism:
This type of reaction is most commonly seen
with the use of seven different drug groups: (i) anti-
convulsants, such as the aromatic anticonvulsants
(phenytoin, carbamazepine, phenobarbital and primi-
done), mexiletine, lamotrigine, valproate, ethosuximi-
de, zonisamide; (ii) antidepressants (desipramine,
amitriptyline, fluoxetine); (iii) sulfonamides and sul-
fones (dapsone, sulfasalazine, trimethoprim-sulfamet-
hoxazole, salozosulphopyridine); (iv) anti-inflamma-
tory drugs (piroxicam, naproxen, diclofenac, sundilac,
phenylbutazone, ibuprofen); (v) anti-infectives (aba-
cavir, cidofovir, terbinafine, nevirapine , minocycline,
linezolid, doxycycline, telaprevir, nitrofurantoin, zalci-
tabine, spiramycin, metronidazole, piperacillin-tazo-
bactam, ceftriaxone); (vi) angiotensin-converting
enzyme inhibitors (captopril, enalapril); (vii) beta-
blockers (atenolol, celiprolol). Cases have been repor-
ted with allopurinol, gold salts, thalidomide, calcium
channel blockers (diltiazem), ranitidine, sorbinil, azat-
hioprine, dobutamine, methimazole, propylthiouracil
and efalizumab. 8
The cases that were more consistent with
DRESS/DIHS were caused by aromatic anticonvulsants,
dapsone, salozosulphopyridine, allopurinol and mino-
cycline. Other drugs causing less typical cases are
reported in the literature, but less frequently. 9
Aromatic anticonvulsants have an estimated occurren-
ce of DRESS/DIHS of one case for every 5,000 people
exposed to the drug, and the reaction is especially
common among black patients. The aromatic anticon-
vulsant drugs that have been most frequently associa-
ted with DRESS/DIHS are phenytoin, phenobarbital
and carbamazepine. However, newer anticonvulsant
medications also containing aromatic structure (felba-
mate, oxcarbazepine, zonisamide and lamotrigine)
and the cross-reactivity between the various aromatic
anticonvulsant drugs are well documented, varying
between 40-80%. Non-aromatic anticonvulsant drugs
(topiramate, levitiracetam, tiagabine, ethosuximide,
valproic acid and gabapentin) appear to be safe. 8
Cacoub et al recently reviewed the literature of
published cases of DRESS and found 44 drugs related
to 172 case reports published in the literature in
PubMed/MEDLINE from January 1997 to May 2009
(Table 1). In about one third of cases, the aromatic
anticonvulsant drugs were more related to the onset
of adverse drug reaction. 10
Some patients experience a prodrome of flu-
like symptoms about 4 weeks before the onset of the
clinical reaction. There are reports of DRESS/DIHS
even in patients using anticonvulsants for about 40
years. 9
The pathogenic mechanism of idiosyncratic
reactions to drugs, such as DRESS/DIHS has not been
DEFINITION
Drug Reaction with Eosinophilia and Systemic
Symptoms (DRESS) syndrome formed by the acronym
derived from the term “Drug Rash with Eosinophilia
and Systemic Symptoms”, coined by Bocquet et al,
also known as Drug-Induced Hypersensitivity
Syndrome (DIHS), was first recognized in 1950 by
Chaiken, in a patient using anticonvulsant. 1,2 There
are many synonyms used, most of them referring to
the origin of the drugs involved in the drug reaction,
such as dapsone syndrome, allopurinol hypersensitivi-
ty syndrome or the anticonvulsant hypersensitivity
syndrome. Although a dermatosis is usual in DRESS,
the extent of skin involvement is variable and therefo-
re the ‘R’ in DRESS was subsequently changed from
‘rash’ to ‘reaction’. 3
Clinically, in its complete form, this syndrome
includes an extensive mucocutaneous rash, fever,
lymphadenopathy, hepatitis, hematologic abnormali-
ties with eosinophilia and atypical lymphocytes, and
may involve other organs with eosinophilic infiltra-
tion, producing damage to several systems, especially
the kidneys, heart, lungs, and pancreas. 4 This multi-
visceral involvement differentiates DRESS from other
common skin reactions to drugs. Another unique fea-
ture of this syndrome is its late onset in relation to the
period of introduction of the causative drug, which
occurs around 3 weeks to 3 months, and their possi-
ble persistence or worsening despite the withdrawal
of the offending drug. 2,5
INCIDENCE
The incidence of this syndrome is estimated to
vary from one case among 1,000 to 10,000 drug expo-
sures. 5,6 Adults are more affected than children, and
although the precise incidence of the drug reaction
has not yet been determined, it is much more com-
mon than Stevens-Johnson syndrome (SJS), which has
an incidence of 1.2 to 6 cases per million persons-year
and most cases are sporadic, with no gender predilec-
tion. Recognition of this syndrome is of paramount
importance, since the mortality rate is about 10% to
20% and a specific therapy may be necessary. 4
ETIOPATHOGENESIS
The exact mechanism of DRESS/DIHS remains
to be determined but, in cases related to anticonvul-
sants drugs, three components are considered: (i)
deficiency or abnormality of the epoxide hydroxylase
enzyme that detoxifies the metabolites of aromatic
amine anticonvulsants (metabolic pathway); (ii) asso-
ciated sequential reactivation of herpesvirus family;
and (iii) ethnic predisposition with certain human leu-
kocyte antigen (HLA) alleles (immune response). 7
436 Criado PR, Criado RFJ, Avancini JM, Santi CG
An Bras Dermatol. 2012;87(3):435-49.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-Induced Hypersensitivity... 437
fully elucidated. 8 Sullivan and Shear proposed a mul-
tifactorial model for the pathogenesis of DRESS/DIHS.
11 Its occurrence would be determined by the combi-
nation of exposure to a drug capable of causing adver-
se reaction given in sufficient dosage and for a certain
period of use to a susceptible patient.
A certain group of drugs associated with
DRESS/DIHS, including the aromatic anticonvulsants,
is metabolized to reactive oxygen intermediates that
appear to be inefficiently detoxified in patients with
acquired or pharmacogenetic variations of the meta-
bolism of these drugs. 5,8,12
Aromatic anticonvulsants such as carbamazepi-
ne, phenytoin and phenobarbital are metabolized by
the hepatic cytochrome P450 (CYP) enzymes and
undergo oxidation by aromatic hydroxylation, with
subsequent formation of arene oxides. Arene oxides
are toxic reactive intermediaries that are normally
enzymatically converted to nontoxic metabolites by
epoxide hydroxylase or gluthatione transferase. In
addition, spontaneous conversion to nontoxic phenol
derivatives can occur. In cases of defective or deficien-
cy of epoxyde hydroxylase, arene oxides can accumu-
late and cause direct cellular toxicity or immune res-
ponse (Figure 1).
Drug interactions can be important in this syn-
drome. Concomitant use of lamotrigine and valproic
acid increases the occurrence of this syndrome. It is
thought that the mechanism for this drug interaction
is the competition between valproic acid and lamotri-
gine for the hepatic metabolism by glucorinidation,
which doubles the half-life of lamotrigine and predic-
tably would increase the rate of adverse effects. 7
Positive patch tests and testing of blast transfor-
mation of lymphocytes indicate the presence of an
immune reaction in which T cells participate in speci-
fic core function. 13,14 Clones of drug-specific T cells
have been isolated from patients sensitive to carbama-
zepine and lamotrigine. 15,16
Sequential reactivation of herpesvirus in
DRESS/DIHS:
Several clinical similarities that could be obser-
ved between DRESS/DIHS and infectious mononu-
cleosis (IM) have led to the implication of a possible
range of viruses as triggers for this syndrome. In addi-
tion, unique features of this syndrome are its late
onset in relation to the period of introduction of the
causative medication and frequent clinical and labora-
tory deterioration, and episodes of exacerbation, des-
pite the withdrawal of the offending drug, so that
these characteristics are not necessarily typical of a
reaction of specific drug etiology. 9
Although there is a conflicting view on the pat-
hogenesis of DRESS/DIHS in different parts of the
world, recent studies have suggested a close relations-
hip between human herpesvirus 6 (HHV-6) and the
development of DRESS/DIHS. 17,18
Drug Cases related
to the Drug
Abacavir 5
Allopurinol 19
Amoxicillin plus clavulanic acid 1
Amitriptyline 2
Atorvastatin 1
Aspirin 1
Captopril 1
Carbamazepine 47
Cafadroxil 1
Celecoxib 1
Chlorambucil 1
Clomipramine 1
Clopidrogrel 1
Codein phosphate 1
Cotrimoxazole / Cefixime 1
Cyanamide 1
Dapsone 4
Diaphenylsulfone 1
Efalizumab 1
Esomeprazole 1
Hydroxichloroquine 2
Ibuprofen 2
Imatinib 1
Lamotrigine 10
Mexiletine 5
Minocycline 3
Nevirapine 8
Olanzapine 1
Oxacarbamazepine 3
Phenobarbital 10
Phenylbutazone 1
Phenytoin 7
Quinine and thiamine 1
Salazosulfapirydine 2
Sodium meglumine ioxitalamate 1
Sodium valproate/ethosuximide 1
Spironolactone 1
Streptomycin 1
Strontium ranelate 2
Sulfalazine 10
Sulfamethoxazole 2
Tribenoside 1
Vancomycin 4
Zinosamide 1
TABLE 1: Drugs related to DRESS/DIHS
Font adapted: Cacoub P et al 10
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Sporadic reports have shown that not only
HHV-6, but also other herpesviruses such as HHV-7,
Epstein-Barr virus (EBV) and cytomegalovirus (CMV)
can be reactivated during the course of the
DRESS/DIHS. 19,20
Results obtained with the analysis by polymera-
se chain reaction showed that various herpesviruses
are sequentially reactivated during the course of the
DRESS/DIHS in most patients. The cascade of viral
reactivation is initiated by EBV or HHV-6 and extends
over a period to HHV-7 and eventually to CMV. 21 In
some patients, the clinical manifestations of this syn-
drome persist despite discontinuation of the drug
involved, coinciding with the reactivation of herpesvi-
rus, as shown in figure 2.
The reactivation of HHV-6 is evidenced by
increases in the titles of IgG anti-HHV-6 and their DNA
levels. HHV-6 is commonly found in the second or
third week after the rash onset, despite the high varia-
bility of the clinical manifestations among patients
with this drug reaction. 9 Since the reactivation of
HHV-6 can be detected only in patients with
DRESS/DIHS, but not other adverse drug reaction in
Japan, this diagnostic test has become sensitive and
specific for diagnosis of all patients with DRESS/DIHS.
17 The detection of HHV-6 reactivation seems to be the
gold standard diagnostic test for DRESS/DIHS in
Japan, other Asian countries and Europe, helping to
confirm the identification of this condition. 9
However, it is still unknown how the viral geno-
me detection in peripheral blood reflects the true sta-
tus of viral reactivation in progress in many different
organs and systems. That is, it is possible that in diffe-
rent compartments and organs such as the spleen and
lymph nodes, different herpes viruses can be reactiva-
ted in sequential order completely independent of
what occurs in the blood, which would explain why
blood samples negative for the viral genome are obtai-
ned during the clinical activity of DRESS/DIHS. 9
What remains unclear is the role of herpesvirus
in early DRESS/DIHS. There are two possibilities:
(i) DRESS/DIHS begin as an “allergic” immune
reaction to a particular drug, which seems to possess
an innate ability to stimulate T cells. 16,22 In the context
of T cell activation is a massive activation of herpesvi-
rus housed in these cells, since the stimulation of T
cells by the drug may reactivate the viral genome into
the cell. So, the drug in turn can activate a specific cel-
lular and humoral immune response to herpesvirus.
This could explain why different herpesviruses are
activated and because in another intense immune pro-
cess, the so-called graft-versus-host disease (GVHD), a
similar reactivation can be observed. 21
(ii) The viral reactivation can occur, but is ini-
tially clinically unapparent. However, T cells stimula-
ted by virus present a significant cross-reactivity with
certain drugs, and exposure to these drugs leads to an
expansion of T cells specific to the drug (and viruses),
FIGURE 1: Hypersensitivity to
 aromatic anticonvulsants. Epoxide
hydrolase deficiency leads to
 reactive oxide arenes accumula-
tion, causing immune response.
(CYP= cytocrome P450)
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which persists even after drug withdrawal due the per-
sistence of viral antigens. The simultaneous appearan-
ce of multiple concurrent viral reactivations could be
explained by the ability of HHV-6 and HHV-7 counter-
parts to reactivate virus. 23 Thus, if the symptoms of
DRESS/DIHS are mediated by both by the various
gene products and by the herpesvirus immune res-
ponses to viral replication, the frequent deterioration
or the several exacerbations that occur despite the
offending drug withdrawal, could be, at least in part,
from the sequential activation of this herpesvirus.
The viral reactivation may provide a “danger
signal” (danger sign) that stimulates massive clonal
expansion of both CD8+ and CD4+ non-specific T cells
and causes the complete development of the syndro-
me. 5,11,24 Shiohara et al, proposed the possibility that
the clinical symptoms during the course of evolutiona-
ry DRESS/DIHS do not seem to be only mediated by
oligoclonal expansion of drug-specific T cells, but also
by antiviral T cells that cross-react with drugs. 17
So are all there is necessary for the occurrence
of DRESS/DIHS are: i) the drugs; ii) the virus, and iii)
their interplay with the immune system. A genetic pre-
disposition has been linked to DRESS/DIHS. 25,26
How is HHV-6 acquired? HHV-6 infects almost
all humans around 2 years of age. 25 Most infections
are caused by the exchange of infected saliva during
the first year of life, although perinatal transmission
can occur. It was demonstrated that the DNA of HHV-
6 can be integrated into the host DNA, and once part
of the human DNA, congenital transmission can occur.
27 This was also demonstrated in the course of the
DRESS/DIHS. 28
The temporal relationship between the onset of
the drug use and the onset of DRESS/DIHS (3 weeks
to 3 months) suggests that viruses have no primary
function in the syndrome, favoring primary pathoge-
nesis related to drug allergy. 9,25
Immune aspects involved in DRESS/DIHS
Patients with DRESS/DIHS have decreased total
serum IgG, IgA and IgM, and B lymphocyte count at
onset while there is an expansion of memory T cells
that cross-react with both drug and virus. 24,29 It is
noteworthy that the lymphocyte transformation test is
negative in the first week of the illness and remains
negative in 90% of the patients after two weeks of the
onset of symptoms, becoming positive only 5-7 weeks
after initiating the drug reaction. 9,25 This could be due
to the expansion of regulatory T cells (which suppress
the proliferation of memory T cells) in the early stages
of the disease and its subsequent reduction by apop-
tosis. 17
Several cytokines are increased during
DRESS/DIHS. In particular, the levels of TNF-�and IL-6,
which are typically pro-inflammatory cytokines, are
elevated on this syndrome before the reactivation of
HHV-6. 30 Interestingly, IL-6 becomes undetectable
during viral replication and increases again after the
infection in most patients. 30
FIGURE 2: DRESS (Drug Reaction
with Eosinophilia and Systemic
Symptoms): successive events,
since drug exposure, onset of
symptoms and viral replication
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DRESS/DIHS is an entity distinct from other
serious adverse drug reactions due to the dynamic
changes in the immune response observed during the
course of the disease. The phenotype of circulating
CD4+ T cells is changed to CD8+ phenotype at the
time of viral reactivation. Regulatory T cells are initial-
ly increased in number in the circulation and skin, but
decrease in parallel with the functional deterioration
of the different organs or systems. Figure 3 summari-
zes the major metabolic changes, immune and viral
infections that are interrelated in the pathogenesis of
DRESS/DIHS in patients who have the syndrome trig-
gered by aromatic anticonvulsants.
The reactivation of HHV-6 is considered a con-
dition requiring immune suppression, demonstrated
on several immune abnormalities in the early syndro-
me: marked decrease of serum immunoglobulins, the
number of circulating B cells and regulatory T cells
dysfunction. 24,31,32 The decrease of IgG, IgA and IgM is
observed at the beginning and the lowest levels are
usually detected several days or a week after withdra-
wal of the triggering drug. After the immunoglobulin
nadir, the recovery to normal levels can be observed
within 1 to 2 weeks after the start of the reaction and
normal levels are usually achieved during the recove-
ry of the disease. 9,17,24
Moreover, the participation of skin inflamma-
tion may be involved in the induction of immunosup-
pressive conditions. 31 Sugita et al demonstrated a
reduction in the number of plasmacytoid dendritic
cells (pDC) in peripheral blood of patients, but an
increase in the expression of these cells in the skin
affected by the rash. 33 The pDC human leukocyte
subtypes are capable of producing large amounts of
interferon alpha (IFNα), which induces the matura-
tion of B cells in order to produce IgG and works well
with critical role in antiviral defense. 34,35 The pDC
from circulation may accumulate in the skin and thus
reduce the number of pDC in the circulation.
Therefore, antiviral responses may be reduced, facili-
FIGURE 3: Sequence of events of drug-virus-immune system interaction in patients with DRESS/DIHS triggered by aromatic anticonvulsants.
Aromatic anticonvulsants are metabolized by the oxidation system of cytochrome P450 (CYP) in arene oxide radicals (intermediate reactive
metabolite) (1a). These arene oxides are detoxified by glutathione transferase and epoxide hydrolase in non-toxic metabolites 2. In geneti-
cally predisposed individuals or by additional factors, occurs an impaired detoxification and accumulation of these metabolites 3, which can
cause cellular damage generating Danger Signs that can stimulate resting T cells, inducing co-stimulatory pathways 4. In addition, ethnic pre-
disposition to certain HLA types may contribute to the formation of neoantigenes from the combination of these intermediary reactive meta-
bolites with tissue macromolecules and formation of haptens (5a), which can be presented via the human histocompatibility complex class
I (HLA -DR) or class II (HLA A, B or C), to CD4 or CD8 T cells 6. It was demonstrated that carbamazepine, valproic acid and amoxicillin are
able to exert immunomodulatory actions by inhibiting histone decaboxilase on B lymphocytes, producing a hypogammaglobulinemia that
precedes the clinical onset of DRESS/DIHS. The clonal expansion of T cells requires sequential reactivation of latent herpesvirus, and at the
same time, CD8 + CLA + T cells are produced, which are directed towards skin, CD8 + CCR4 + T cells addressed to the lungs (7b) and CD4
+ IL4, IL5 producer and IL17 CD4Th17 + producer that cause tissue and peripheral eosinophilia
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tating viral reactivation in peripheral blood and tis-
sues other than the skin. 31
Although the terms DRESS and DIHS are often
and mistakenly used interchangeably, there is curren-
tly a tendency to believe that the DIHS represents the
most severe cases of DRESS, with reactivation of HHV-
6 detected in a large majority of patients and only in
a limited number of patients with DRESS. 31,36
Associations of HLA alleles with DRESS/DIHS
and maculopapular eruption induced by aromatic anti-
convulsants or other drugs (pharmacogenomics):
The most used hypothesis to explain the immune-aller-
gic reactions to drugs is the theory of hapten / pro-hap-
ten: according to this hypothesis, the drug (or metabo-
lite) is processed by antigen presenting cells (APC) and
expressed in the cell membrane in the context of
human leukocyte antigen (HLA A, B or C) type I (MHC
I) or HLA-D type II (MHCII). The complex HLA-drug
(hapten) is presented to native T cells (naive) via their
T cell receptor (TCR), which initiates different types of
immune responses, depending on the HLA expressed
on the APC and the cytokine environment.
The true story of correlation “HLA-drug” began
on the twenty-first century with abacavir. In 2002,
two independent groups observed the abacavir
hypersensitivity syndrome and that this was restricted
to the allele HLA-B * 5701, which conferred an eleva-
ted odds ratio (> 100). The GlaxoSmithKline
(London, UK) led the largest international randomi-
zed pharmacogenetic clinical trial to date, which
demonstrated the correlation between abacavir
hypersensitivity reactions and patients with this alle-
le, and proved that the exclusion of abacavir intro-
duction to the patients that had this allele resulted in
the disappearance of the syndrome, which was first
seen in 5% of patients overall who received the drug
during the first weeks of antiretroviral treatment.
This allele test is now routinely used before the intro-
duction of abacavir in several countries.
Some ethnic groups and genetic basis seems to
facilitate certain types of adverse drug reactions
(Table 2). 37
The HLA alleles have a high negative predictive
value but low positive predictive value in relation to
adverse drug reactions, indicating that these biogene-
tic markers are necessary but not sufficient to trigger
the allergic immune reactions. According to the theo-
ry of HLA-drug (hapten), the complex hapten only
triggers an immune-allergic reaction in the presence
of a specific HLA allele.
Thus, prospective HLA screening should pre-
vent some patients from having serious idiosyncratic
reactions, such as DRESS/DIHS, Stevens-Johnson syn-
drome (SJS) and toxic epidermal necrolysis (TEN) if
they have a specific risk allele by not receiving the
drug related to it. The HLA pharmacogenomics is a
field of recent study that has been rapidly developed
and implemented into clinical practice and has impro-
ved drug prescription, which is likely to become more
and more important in coming years.
Besides causing SJS and TEN, carbamazepine
also induces other types of adverse drug reactions,
including maculopapular exanthema (MPE) and
DRESS/DIHS. 38 The association between HLA-B*1502
and carbamazepine MPE-induced was not detected in
populations of ethnic Han Chinese and Hong Kong or
Thai populations. 39,40,41 Studies involving 18 patients
Han Chinese residents in Taiwan and 56 Caucasians
showed no association between cases of DRESS/DIHS
caused by carbamazepine and HLA-B*1502. 42 These
data indicate that the association between HLA-
B*1502 and cutaneous adverse drug reactions indu-
ced by carbamazepine are specific to SJS/TEN. 38
Kano et al  showed that 4 of their 13 Japanese
patients (30.8%) with DRESS/DIHS in which it was
proved reactivation of HHV-6 and the syndrome was
triggered by aromatic anticonvulsants (carbamazepine
10; phenobarbital in 2 and phenytoin in 1) had HLA-
B*1301. 43 The frequency of this allele was much hig-
her than the Japanese population in which it is 1.3%.
44 Although this difference was not statistically signifi-
cant after correction for multiple comparisons, the
authors proposed that the presence of certain alleles
of HLA-B on the reactivation of the virus contributed,
at least in part, for the association of HLA-B allele with
DRESS/DIHS.
Kashiwagi et al demonstrated a significant asso-
ciation between adverse skin reactions to carbamaze-
pine and HLA-A* 3101 among 22 Japanese patients,
including erythema multiforme, erythroderma,
DRESS/DIHS, SSJ and other drug reactions. 45 Eleven of
these patients (50%), including 2 patients with SJS
and others, were carriers of HLA-A*3101 and allele fre-
quency was much higher in the patients (25%) than in
the Japanese population (7.1%) (P = 4x10-4, OR =
4.33).
Hung et al studied 18 patients Han Chinese
with MPE induced by carbamazepine and also found
an association with HLA-A * 3101 (P = 2.2 x10; OR =
17.5). 41 The sample size of those studies was small, so
further studies with larger population samples may or
may not clarify the association of HLA-A*3101 allele as
a risk for adverse drug reactions.
In a case-control study in a Han-Chinese popu-
lation, Hung et al found a strong association between
the presence of HLA-B*5801 and SJS / TEN, or
DRESS/DIHS triggered by allopurinol among 51
patients (100%), compared with 20 out of 135 (15%)
allopurinol-tolerant patients and 19 out of 93 control
people (20%) (P <6.10, OR = 580). 46
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Dainichi et al  showed that Japanese patients
with different clinical types of cutaneous adverse drug
reactions caused by allopurinol, including SJS, TEN
and DRESS/DIHS, had the same allele HLA-B*5801. 47
Pirmohamed et al found an increased frequen-
cy of HLA-DR3 and HLA-DQ2 in a group of patients
with carbamazepine-induced DRESS/DIHS (respecti-
vely P = 0.01, OR = 3.3 and P = 0.04, OR = 2.7). 48 It
was demonstrated that activation of CD4+ T cells with
interleukin-2 (IL-2) is essential for the spread of HHV-
6 in vitro. Genotyping of patients revealed that they
had positive HLA-DR3 (DRB1*0301) and HLA-DQ2
(DQB1*0201).
Thus, in recent years the attention given to
genetic factors as cause to the variation in both the
interpersonal effectiveness and adverse effects to
medicines has increased. Idiosyncratic reactions are
often immune-mediated, usually severe, and have an
unpredictable course. The main region of human DNA
that has genetic variations that predispose to drug
hypersensitivity reactions is the region of the human
leukocyte antigen (HLA). This region harbors the gene
locus of most diseases and contains many genes asso-
ciated with immune functions. 49
Although strong associations have been
demonstrated between certain HLA alleles and some
types of adverse skin reaction to drugs, there is no
definitive evidence or published data concerning the
functions involved in these alleles. The activation of T
cells restricted to HLA is necessary for the induction of
immune reactions and, moreover, there is the possibi-
lity that some HLA proteins have high binding affinity
with other drugs or a metabolite of the drug through
covalent and non-covalent mechanisms. On the other
hand, a protective effect of HLA has also been sugges-
ted. 38 Alfirevic et al reported a potential protective
Drug (population) SJS/TEN DRESS MPE Reference
Carbamazepine (Han HLA-B*1502 (Pc 3,1x rs 2894342 motilin HLA-A*3101 (Pc •Nature 
Chinese-Taiwan 10-27 a 1,6x10-41; gene (Pc 0,0064; 2,2x10-3; OR 17,5) 2004;428:486.
OR 1,37-2,504) OR 7,1) •Pharmacogenet 
Genomics 
2006;16:297-306.
Carbamazepine Weak association Haplotypes TNF-308- Unknown •Neurology 
with B44. DR3-DQ2 2001;56:890-6.
(Caucasian Europeans) No association with (Pc 0,02; OR 3,2) •Pharmacogenomics J
HLA-B * 1502 2006;6:265-8.
•Pharmacogenomics 
2006;7:813-8.
Carbamazepine HLA-B*1502 Unknown Unknown •Pharmacogenomics J
(Southeast Asia) 2006;6:265-8.
Allopurinol Chinese: HLA-B*5801 (Pc 4,7x10-24 OR 580,3) Unknown •Proc Natl Acad Sci
(Han Chinese-Taiwan and Europeans: HLA-B* 5801 (P10-6 OR 80) USA 2005;102:4134-9.
Caucasian Europeans) •Pharmacogenet 
Genomics 2008;
18:99-107.
Allopurinol (Han HLA-B17/BW58  (Pc 2,9x10-9 RR 46,3) •Dermatologica 
Chinese-Singapure) 1989;179:32-33.
Abacavir (Caucasians ) HLA-B*5701 (Pc 5,2x10-20 OR 960) •Proc Natl Acad Sci 
USA 2004;101:4180-5.
Abacavir (Hispanic No association with HLA-B*5701 •Pharmacogenomics 
or Africans) 2004;5:203-11.
Nevirapine HLA-DRB1*0101 HLA-B*3505 in •AIDS 2005;19:97-9.
(Australia) Thai (P=0.00017; •Pharmacogenet 
OR 49,15) Genomics
2010;19:139-42.
TABLE 2: Ethnic groups and genetic basis related to adverse drug reactions
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effect of HLA-B*0702 against severe adverse skin reac-
tions induced by carbamazepine in Caucasian
patients. 42
The implications of pharmacogenomics are
varied, one example is the recommendation by the
Food and Drug Administration (FDA), that currently
recommends genetic testing for users of more than
ten drugs currently marketed in that country. 38
HISTOPATHOLOGY
Histopathology of the skin shows a diffuse
dense lymphocytic infiltrate or superficial and perivas-
cular. Eosinophils in the dermis or swelling may or
not be present (Figure 4). On some occasions there is
a band-like infiltrate with atypical lymphocytes simula-
ting epidermotropism like mycosis fungoides. 1
Fernando et al described a patient with
DRESS/DIHS triggered by carbamazepine. The biopsy
of the rash presented an unusual form of superficial
perivascular inflammatory infiltrate, in which tiny gra-
nulomas along with a moderate number of lymphocy-
tes could be found. 50 The authors speculated that gra-
nuloma formation may be due to a sustained exposu-
re to the drug, even after the onset of DRESS/DIHS.
The expansion of CD4+ T cells producing interferon
and other cytokines results in recruitment of macrop-
hages, which as a result of maintained exposure to the
drug and persistence of cytokine release, promotes
differentiation of macrophages into epithelioid cells,
which secrete TNF, which promotes fusion of these
cells into multinucleated giant cells.
Thus, biopsies of organs involved in
DRESS/DIHS, such as skin and liver, on a significant
number of patients may demonstrate the true frequen-
cy of granulomatous infiltration in the disease and assist
in understanding the pathogenesis of the reaction. 50
SYMPTOMS AND SIGNS
The syndrome usually develops within two
months after drug introduction, more often in 3
weeks to 3 months of the introduction of the drug, or
in brief if constitutes a re-administration. 17 Fever,
often high (38-40oC), which is the most common
symptom (seen in 90-100% of cases) and rash (87% of
cases) are the first signs, especially when related to
antiepileptic drugs. 25,51-55 The cutaneous eruption con-
sists of a morbilliform rash, which is also common in
other less severe drug reactions and both presenta-
tions are indistinguishable (Figures 5 and 6). 56
The face, upper trunk and upper extremities are
initially affected, with subsequent progression to the
An Bras Dermatol. 2012;87(3):435-49.
FIGURE 4: Epidermis showing spongiosis, apoptotic keratinocytes,
exocytosis of lymphocytes and inflammatory infiltrate on the
superficial dermis. The formation of epithelioid cell granuloma is
observed on the superficial dermis, which was sporadically
 reported in cases of DRESS/DIHS
FIGURE 5: Morbilliform exanthem in a man with DRESS/DIHS
 caused by the use of anticonvulsants
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lower extremities, occurring in about 90% of cases,
which later spreads to the legs and an erythrodermic
rash can be developed. 8
The maculopapular eruption later becomes
infiltrated with edematous follicular accentuation.
Swelling of the face, with marked periorbital involve-
ment, is a warning to the diagnosis, occurring in
about 25% of patients, and can be so intense that the
patient becomes disfigured. Vesicles may arise and
fine vesicles by edema of the dermis can be present.
8,54 No necrosis of the epidermis like TEN occurs,
except in rare cases of overlapping DRESS/DIHS and
TEN. 1,57 Small sterile perifollicular pustules and non-
follicular pustules may appear, which are different
from acute generalized exanthematous pustulosis,
and does not predominate on the main folds of the
skin. 53 Often atypical targets may arise. 51,52 Over time
the rash becomes purplish, sharply lower limbs and
the resolution is scaling. 8,53 Another form of presenta-
tion is a picture of exfoliative dermatitis, which may
be associated with mucosal involvement, such as chei-
litis, erosions, pharygitis and enanthematous enlarged
tonsils. 3,58
Bilateral edema and infiltration of the salivary
glands with xerostomia has been frequently reported. 25
Lymphadenopathy is common (70-75% of
cases), limited to the lymph nodes or generalized,
painful, gradually resolving with the withdrawal of the
drug. 25 The lymph nodes may reveal two distinct
types of involvement: a benign pattern of lymphoid
hyperplasia with maintenance of normal lymph node
architecture, and other standard pseudolymphoma-
tous aspect, with obliteration of normal architecture
by a polymorphous infiltrate composed of atypical
cells, plasma cells, histiocytes and eosinophils, with
areas of necrosis, edema and mitotic figures but no
Reed-Sternberg cells or capsular invasion. This histo-
pathological pattern can simulate a malignant lymp-
homa. 1
Various hematologic abnormalities are obser-
ved, which consist of marked leukocytosis, eosinophi-
lia (30% of cases) and atypical lymphocytes similar to
mononucleosis. 1,25 These findings guide the diagnosis
toward DRESS, however, can sometimes be difficult to
distinguish from viral infections such as infection by
Epstein-Barr virus or hematologic diseases.
Lymphopenia, leukopenia or leukocytosis usually pre-
cede, although they often are not detected because
they occur several days before installation of the clini-
cal syndrome. Leukocytosis may be high, up until
50,000 leukocytes/mm3, and eosinophilia reaches
values  higher than 20.000/mm3. 1 The eosinophilia
may determine the involvement of internal organs
with pulmonary infiltrates. In general, eosinophilia
may be observed, about 1 to 2 weeks after the onset of
the syndrome, or even occur after the increase in liver
enzymes has normalized. 59
Hemophagocytic syndrome (HPS) can rarely be
observed in the course of DRESS/DIHS. HPS is associa-
ted with and triggered by various conditions, including
viral infections, particularly EBV, malignant tumors, or
autoimmune diseases. When in the course of the
DRESS/DIHS, HPS usually occurs two weeks after the
onset of drug eruption. There is a decrease in white
blood cells and platelets that is detected simultaneous-
ly with the elevation of lactate dehydrogenase (LDH).
Bone marrow aspirate revealed hemophagocytosis
figures in an increased number of macrophages. 59
Multiorgan involvement may include a wide
variety of organs and systems with myocarditis/myosi-
tis, pericarditis, interstitial nephritis (11% of cases),
necrotizing granulomatous vasculitis in kidney, brain
involvement (encephalitis or meningitis), colitis and
thyroiditis. 1,59 This potentially fatal visceral involve-
ment form, may be symptomatic or not, and initiates
1 to 2 weeks after the onset of a rash. 1,51,52,53,54 We
observed a patient who developed acute pancreatitis
and has evolved into a lethal course. 51
There are reports of shock and respiratory dis-
tress syndrome with hypotension, pyrexia, hepatitis
and renal failure related to a hydantoin reaction. 25
Arthritis or arthralgia may occur in the context
of this syndrome, including myositis 1.
Liver involvement is the most common visceral
manifestation (50-60% of patients), after the lympha-
denopathy. Hepatomegaly may constitute a finding on
physical examination. Hepatitis with isolated eleva-
tion of liver transaminases is common (51% of cases),
usually anicteric, but liver failure contributes to the
leading causes of death 1. Liver biopsy shows central
FIGURE 6: DRESS/DIHS induced by dapsone in a 26 years old
patient receiving treatment for Leprosy. The patient died due to
hepatic failure
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lobular necrosis and dense inflammatory infiltrate of
lymphocytes and eosinophils or granulomas. 1,59 The
reaction is accompanied by cholestasis and hepatocy-
te necrosis 1. In more severe cases, widespread or
focal hepatic necrosis may be present. 1,60 The presen-
ce of an active co-infection with hepatitis viruses B
and/or C often determines a deterioration of the liver
function and prolongs liver dysfunction. 59,60
There are few cases reported in the literature of
DRESS/DIHS with severe acute hepatitis (defined by
the presence of ALT to more 10x ULN and / or acute
liver failure, such as coagulopathy and encephalopat-
hy), mostly observed in women between the second
and fourth decade of life, especially related to the use
of sulfasalazine. 50,59 About 15% result in death or liver
transplantation, and the course of the disease is appa-
rently unchanged by the use of immunosuppressant.
50 The fast recognition of the syndrome and prompt
withdrawal of the drug can limit the liver damage, alt-
hough this may possibly even worse for several weeks,
and take months to resolve.
Renal involvement occurs in about 11% of
cases, being particularly evident in cases arising from
the use of allopurinol. 59 There was an increase in
serum creatinine and urea and decreased creatinine
clearance. In urine I tests, increased content of eosi-
nophils can de observed. 59
Although pulmonary involvement is rarely
reported in DRESS/DIHS, interstitial pneumonia with
eosinophilia is often observed among patients who
had the syndrome triggered by minocycline. 25 Possibly
the cases with lower intensity of pulmonary manifes-
tations are less reported, leading to a bias in the publi-
cations. Pulmonary complications include acute
interstitial pneumonitis, lymphocytic interstitial pneu-
monia and adult respiratory distress syndrome
(ARDS). 25
Myocarditis may develop at the beginning of
the syndrome or up to 40 days after installation.
Symptoms include heart failure, chest pain, sudden
tachycardia, dyspnea, and hypotension in early
DRESS/DIHS, but some patients are asymptomatic.
The echocardiogram shows a reduction in ejection
fraction, chest x-ray demonstrates cardiomegaly and
the electrocardiogram shows nonspecific changes in
the segment ST-T. There is an increase of enzymes
such as CPK and CK-MB, but no apparent changes in
levels of troponin-1. 59
Neurological complications include meningitis
and encephalitis. Meningoencephalitis occurs about 2
to 4 weeks after onset of the drug reaction, and may
determine coma, seizures, headaches and disorders of
speech, and paresis and paralysis of cranial nerves. 59
Gastrointestinal bleeding may be an abrupt
complication caused by ulcers caused by CMV.
Endoscopic examination reveals arterial bleeding from
punched-out gastric ulcerations. 59
Kennebeck compiled the frequency of clinical
manifestations and laboratory data of the anticonvul-
sant hypersensitivity syndrome: Fever (90-100%), cuta-
neous eruption (87-90%), limphadenopathy (70%),
hepatitis (50-60%), hematological abnormalities (23-
50%), periorbital and orofacial edema (25%) , myalgia
and arthritis (20%), nefritis (11%), pharyngitis (10%),
pulmonary manifestation (9%).61
The visceral involvement in acute DRESS/DIHS
until resolution of the clinical disease is, therefore,
extensive and varied, and some of these events are clo-
sely related to human herpervirus reactivation, and
include: enterocolitis and intestinal bleeding, hemop-
hagocytic syndrome (HPS), hepatitis, limbic encepha-
litis, myocarditis, nephritis, mumps, pneumonia and
pleurisy, and the syndrome of inappropriate antidiu-
retic hormone hypersecretion (SIADH). 59
The exclusion of other serious infections, parti-
cularly bacteremia, neoplastic diseases (lymphoma,
leukemia, hypereosinophilic syndrome, paraneoplas-
tic), autoimmune or connective tissue conditions
(adult-onset Still’s disease, lupus erythematosus, vas-
culitis) is necessary for an accurate diagnosis
DRESS/DIHS. 25,62,63
Complications are rare and include limbic
encephalitis, thyroid disease, renal failure, splenic
rupture, eosinophilic colitis, eosinophilic esophagitis,
enterocolitis and fatal CMV. 64
Death rate can reach 20%, especially in cases
related to advanced age, renal impairment, jaundice
and hepatitis with reactivation of CMV. In contrast,
cases where there is a reactivation of Epstein-Barr virus
(EBV) seems to have less a severe course, but are more
likely to have later development (usually after several
years) of autoimmune diseases such as diabetes melli-
tus type 1 and autoimmune hypothyroidism. 25
Several authors have reported the occurrence of
autoimmune diseases and/or the production of
autoantibodies after the resolution of DRESS/DIHS, in
a period ranging from several months or years after
the resolution of the syndrome, and some are similar
to those seen after bone marrow transplantation. The
related conditions include diabetes mellitus type 1,
lupus erythematosus, Hashimoto’s thyroiditis, entero-
pathy, sclerodermiform lesions type graft-versus-host
disease (GVHD) and bullous pemphigoid. 59
DIAGNOSTIC CRITERIA
The diagnosis is difficult since there are incom-
plete clinical features or less characteristic, for exam-
ple, hepatitis without rash, or just a pulmonary infil-
trate with eosinophilia. Bocquet, Bagot and Roujeau 1
were the first authors who proposed criteria for
An Bras Dermatol. 2012;87(3):435-49.
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DRESS diagnosis. According to these authors the diag-
nosis is established if there are at least three criteria
present: 1. Drug rash; 2. Hematologic abnormalities
(a. Eosinophilia > 1.500/mm3; b. Presence of atypical
lymphocytes); 3. Systemic involvement [Adenopathy
(> 2 cm in diameter) or hepatitis (transaminase eleva-
tion of at least twice the normal values) or interstitial
nephritis or pneumonitis or carditis].
There is still no international consensus on the
best criteria for the definition of DRESS/DIHS diagno-
sis. 65 Bocquet et al and Southeimer & Houpt have
proposed different definitions and nosology for
DRESS/DIHS, in order to clarify clinical and patholo-
gical characteristics of this syndrome. 1,66
The Japanese study group of severe cutaneous
adverse reactions to drugs (SCAR-J) has adopted other
criteria, as presented on table 3. 17
However, the universal adoption of these crite-
ria may be impaired, because one of the criteria is the
viral replication during the course of infection, and
some tests, such as measurement of IgG titer anti-
HHV-6 (human herpesvirus type 6), are not yet wide-
ly available in all hospitals or laboratories routine.
In our view, the criteria adopted by the
European group RegiSCAR is the one that best meets
the needs in the diagnosis of DRESS/DIHS, published
by Kardaun et al in 2007. It was suggested the use of
a score system for the diagnosis of DRESS/DIHS,
based on the presence of symptoms and clinical and
laboratory signs, which can be seen on table 4. 67
Complementary tests during follow-up of patients
with DRESS/DIHS:
Given the suspicion of the syndrome relevant
exams should be performed, keeping in mind that this
syndrome has an evolutionary behavior. 63 The initial
tests are oriented in order to verify the data and
research into hematological visceral involvement, as
proposed by Descamps et al: At admission: complete
blood count, ALT, AST, total bilirrubin, GGT, alkaline
phosphatase, sodium, potassium, creatinine and crea-
tinine clearance, 24h urine protein and urinary eosi-
nophil count, CPK, LDH, ferritin, triglycerides, cal-
cium and PTH, blood glucose, TAP and TTPA, lipase,
protein electrophoresis, c-reactive protein, quantitati-
ve PCR for HHV-6, 7, EBV and CMV, blood culture,
anti-nuclear factor. 68
Follow up (two times/week): complete blood
count, ALT, AST, creatinine, LDH, other laboratory
tests according to changes found on admission tests.
Evolutive follow up: quantitative PCR for HHV-6, 7,
EBV and CMV, complete blood count, ALT, AST, alkali-
ne phosphatase, creatinine, LDH, ferritin and triglyce-
rides.
TREATMENT 
The early recognition of adverse drug reaction
and withdrawal of the offending drug are the most
important and essential steps toward the clinical
improvement. Empirical treatment with antibiotics or
anti-inflammatory drugs should not be administered
during the acute disease, since they may confuse or
worsen the clinical picture of patients due to an unex-
plained cross-reactivity between drugs. 17
The prognosis is generally worse in the elderly
while the recovery is usually faster and complete in
children.
For many years, the treatment of DRESS has
been based on the use of systemic corticosteroids
(dose equal to or greater than 1 to 1.5 mg/kg /day of
prednisone or equivalent) with marked improvement
of symptoms and laboratory parameters, but several
days after the start of treatment. 1, 17, 25 Systemic corti-
costeroids should have their dose reduced, after the
clinical and laboratory control of the disease, slowly
over 6-8 weeks in order to prevent a recurrence of the
symptoms of the disease. Abrupt deterioration of
various symptoms is observed when the withdrawal is
accidental or by rapid reduction of the doses of corti-
costeroids. 17,69 Shiohara et al  recommend that all
patients should be hospitalized even when the initial
presentation is mild. 17
If symptoms get worse despite the use of oral
corticosteroids, other options used in case series are
the use of pulsed methylprednisolone (30mg/kg intra-
venously for 3 days), intravenous immunoglobulin
1. Maculopapular rash developing＞ 3 weeks after starting
therapy with a limited number of drugs
2. Persistent clinical findings after drug withdrawal
3. Fever (＞38°C)
4. Hepatic abnormalities (TGP > 100 U/L)
5. Leukocyte abnormalities (at least one present)
a. Leukocytosis (＞11.000/mm3)
b. Atypical lymphocytosis (>5%)
c. Eosinophilia (>1.500/mm3)
6. HHV-6 reactivation
TABLE 3: SCAR-J diagnostic criteria for DRESS/DIHS
The diagnosis is confirmed by the presence of the seven criteria
(typical DIHS) or of the first five criteria (atypical DIHS).
* This can be replaced by other organ involvement such as renal
involvement.
+ Reactivation is detected from second to third week after
 symptoms onset, through IgG anti-HHV-6 titers elevation.
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(IVIG), and plasmapheresis, or a combination of these
therapies. 17,70 It should be remembered that the
immunosuppressive therapies may increase the risk of
infectious complications and sepsis. Mild cases can
recover just by drug withdrawal and supportive treat-
ment after a few weeks, even without the use of corti-
costeroids. However, even in mild cases, the monito-
ring of liver function tests should be performed and
appropriate tests ordered to rule out the involvement
of other organs like lungs, thyroid and heart. 17
Special attention should be given to a possible
reactivation of CMV, especially in patients with severe
DRESS/DIHS. Physicians should also pay attention to a
proper balance between the needs of corticosteroids
for relief of symptoms and clinical signs and their pos-
sible negative interference on viral load.
High doses of IVIG have two immunological
effects: (i) compensates for the decrease in concentra-
tion of immunoglobulins in the patient’s blood and
the defects of the immune protection against HHV-6,
(ii) high doses of IVIG have an anti-inflammatory effect
that can regulate immune responses, as seen in the
treatment of autoimmune diseases. 70
The group of drug reactions of the French
Society of Dermatology published the results of a con-
sensus of experts on the therapeutic management of
DRESS/DIHS: 68
• Absence of signs of severity: topical corticos-
teroids (potent or very potent), emollients, H1-antihis-
tamines;
• Presence of signs of severity (transaminases >
5 times normal, renal involvement, pneumonia,
hemophagocytosis, cardiac, etc.): corticosteroids equi-
valent to 1 mg / kg per day of prednisone, multidisci-
plinary evaluation;
• Life-threatening signs (hemophagocytosis
with bone marrow failure, encephalitis, severe hepati-
tis, renal failure, and respiratory failure): steroids
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Score -1 0 1 2 MAX MIN
Fever ≥ 38,5OC No / U Yes -1 0
Enlarged lymph nodes No / U Yes 0 1
Eosinophilia: No / U 0 2
Eosinophils 0.7-1.499 x ≥1.5 x 
109L-1 109 L-1
Eosinophils, IF leucocytes < 4.0 x 109L-1 10%-19,9% ≥20%
Atypical lymphocytes No / U Yes 0 1
Skin Involvement: -2 2
Skin rash extent (% body surface area) No / U >50%
Skin rash suggesting DRESS No U Yes
Biopsy suggesting DRESS No No / U
Organ involvement*: 0 2
Liver No / U Yes
Kidney No / U Yes
Muscle / heart No / U Yes
Pancreas No / U Yes
Other organs No / U Yes
Resolution ≥ 15 days No / U Yes -1 0
Evaluation of other potential causes:
Antinuclear antibody (FAN)
Blood culture
Serology HAV / HBV / HCV
Chlamydia / Mycoplasma
*If none positive and ≥ 3 of above negative Yes 0 1
Total score -4 9
TABLE 4: RegiSCAR diagnostic criteria for DRESS/DIHS
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generally associated with intravenous immunoglobu-
lin (IVIG) at a dose of 2 g / kg over five days. The IVIG
should not be used without associated steroids. These
treatments will be conducted through multidisciplina-
ry evaluation;
• Presence of signs of severity with confirma-
tion of a major viral reactivation: Combining steroids
and antiviral (Ganciclovir) and/or IVIG.
Take home messages:
• DRESS/DIHS is an adverse drug reaction cau-
sed by an apparent group of drugs, and one third of
the cases are related to anticonvulsants, in addition to
sulfonamides and allopurinol, which can cause 10-
20% mortality.
• The syndrome is characterized by a latency
period ranging from 3 weeks to 3 months after the
introduction of the offending drug, and its course is
marked by apparent sequential reactivation of human
herpesvirus and subsequent development of autoim-
mune diseases, providing an opportunity to establish
a connection between viral infections and the emer-
gence of autoimmune diseases.
• In the early DRESS/DIHS hypogammaglobuli-
nemia and reduced peripheral B cell are found and
CD4 + CD25 + FoxP3 + (regulatory T cells) are eleva-
ted at the beginning of the syndrome, regardless of
whether or not the patients are treated with corticoste-
roids. This clonal expansion of regulatory T cells
appears to prevent activation of anti-viral T cells in an
appropriate manner and several sequential reactiva-
tion of virus is presented in the syndrome. These regu-
latory T cells have the phenotype CCR4+ and CLA+,
which addresses the skin. In the last stage of the syn-
drome’s activity, phenotype of cytotoxic T cells become
prominent and CD4+ lymphocytes become intensely
diminished. These cells are depleted over time, suffe-
ring apoptosis and becoming reduced after the resolu-
tion of the syndrome, which could be a predisposing
factor for the development of autoimmunity. ❑
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